Prior to this approval, NSCLC therapeutics relied on the use of first-generation (erlotinib and gefitinib) and second-generation (afatinib and dacomitinib) EGFR inhibitors that would inevitably become inefficient because of the emergence of the EGFR T790M mutation [38,39]. Here, EGFR is linked to non-small cell lung carcinoma.